Composition (per 1 ml):
Active ingredient: Chondroitin sodium sulfate (in terms of dry matter) - 100.0 mg Excipients: Sodium disulfite - 2.0 mg Methyl parahydroxybenzoate - 0.5 mg 1 M sodium hydroxide solution - to pH 6.0 - 7.5 Water for injection - up to 1.0 ml Description: Transparent, colorless or slightly yellowish solution.

Pharmacotherapeutic group: tissue repair stimulator.
ATX code: M01AX25.

Pharmacological properties.
Chondroitin sulfate is the main component of proteoglycans, which together with collagen fibers make up the cartilage matrix.

It has chondrostimulating, regenerating, anti-inflammatory and analgesic effects. Chondroitin sulfate is involved in the construction of the basic substance of cartilage and bone tissue. Has chondroprotective properties; enhances metabolic processes in hyaline and fibrous cartilage and subchondral bone; inhibits the activity of enzymes that cause degradation (destruction) of articular cartilage; stimulates the production of proteoglycans by chondrocytes; influences phosphorus-calcium metabolism in cartilage tissue, stimulates its regeneration; participates in the construction of the basic substance of bone and cartilage tissue. It has anti-inflammatory and analgesic properties, helps reduce the release of inflammatory mediators and pain factors into the synovial fluid through synoviocytes and macrophages of the synovial membrane, and suppresses the secretion of leukotrienes and prostaglandins. The drug prevents connective tissue degeneration and reduces calcium loss, accelerating bone tissue restoration processes.
Chondroitin sulfate slows the progression of osteoarthritis and osteochondrosis. Promotes the restoration of the joint capsule and cartilaginous surfaces of the joints, prevents the collapse of connective tissue, and normalizes the production of joint fluid.
The clinical effect is manifested by an improvement in joint mobility and a decrease in pain intensity, while the therapeutic effect persists for a long time after the end of the course of therapy. When treating degenerative changes in joints accompanied by secondary synovitis, the effect is observed within 2-3 weeks from the start of the course.

Possessing structural similarity to heparin, it can potentially prevent the formation of fibrin thrombi in the synovial and subchondral microvasculature.

Absorption

After intramuscular administration, the maximum concentration in blood plasma (Cmax) is achieved after 1 hour, then the concentration of the drug gradually decreases over 2 days.

After a single intra-articular injection in a dose of 2 ml, the Cmax of chondroitin sulfate in the blood plasma is observed after 1-2 hours and is 52.5-86.9 ng/ml.

Distribution

Chondroitin sulfate is quickly distributed after intramuscular administration: after 30 minutes the drug is found in significant concentrations in the blood; after 15 minutes - in the synovial fluid.

Accumulates mainly in cartilage tissue (maximum concentration in articular cartilage is achieved after 48 hours); the synovial membrane is not an obstacle to the penetration of the drug into the joint cavity.

After intra-articular administration, chondroitin sulfate is retained in the joint tissues and gradually released into the bloodstream.

Elimination

It is excreted from the body mainly by the kidneys within 24 hours.

The half-life (T1/2) for intra-articular administration is 2.5 hours.

Degenerative-dystrophic diseases of the joints and spine:
- osteoarthritis of peripheral joints;
- intervertebral osteochondrosis and osteoarthrosis.

Hypersensitivity to chondroitin sulfate or to any of the components of the drug.

Bleeding, tendency to bleed.

Thrombophlebitis.

With intra-articular injection: the presence of active inflammatory or infectious processes in the joint, the presence of an active skin disease or skin infection in the area of ​​the intended injection.

Pregnancy, lactation (there are no data on the safety of the drug during pregnancy and lactation).

Children under 18 years of age (there are no data on the effectiveness and safety of the drug in pediatric practice).

Use during pregnancy and breastfeeding

There are currently no data on the safety of the drug. It is contraindicated to use INJECTRAN® during pregnancy and breastfeeding.

Intramuscular and intraarticular administration.

Intramuscularly, 1 ml every other day. If well tolerated, the dose is increased to 2 ml, starting with the fourth injection. The course of treatment is 25-30 injections. If necessary, a second course of treatment can be carried out after 6 months. The duration of repeated courses of treatment is determined by the doctor.
For osteoarthritis of large joints, a combination of intra-articular and intramuscular routes of administration is possible. Up to 5 intra-articular injections of 2 ml are administered with an interval of 3 days between injections and 16 intramuscular injections of 2 ml with an interval of 1 day between injections (every other day). Depending on the size of the joint, up to 2 ml of INJECTRAN® can be injected into the joint cavity.

After intra-articular administration of the drug, the puncture site is lubricated with an alcohol wipe, and a bactericidal patch is applied.

Intra-articular administration of the drug is carried out under aseptic conditions by a specialist trained in the technique of intra-articular administration!

Immune system disorders: allergic reactions (skin itching, erythema, urticaria, dermatitis).

General disorders and reactions at the injection site: hemorrhages at the injection site.

Overdose

Currently, no cases of overdose of INJECTRAN® have been reported. However, it can be assumed that if the daily dose is exceeded, the detection of side effects of the drug may increase. Treatment is symptomatic.

Interactions with other drugs

The effect of indirect anticoagulants, antiplatelet agents and fibrinolytics may be enhanced, which requires more frequent monitoring of blood coagulation parameters when used together.

Shows synergistic action when used simultaneously with glucosamine and other chondroprotectors.

The drug contains sodium disulfite, which can cause severe hypersensitivity reactions and bronchospasm.

Impact on the ability to drive vehicles and machinery

INJECTRAN® does not affect the ability to drive vehicles and operate machinery.

Solution for intramuscular and intraarticular administration, 100 mg/ml.

1 or 2 ml in ampoules with a break point or ring of neutral glass NS-3 or glass with hydrolysis resistance class HGA1 (first hydrolytic).

5 ampoules are placed in a blister pack made of PVC film with aluminum foil or self-adhesive film, or without foil and film.

1 or 2 blister packs along with instructions for use are placed in a cardboard pack.

5 or 10 ampoules along with instructions for use are placed in a cardboard pack with a corrugated liner.

The pack is additionally coated with two protective perforated labels made of polypropylene biaxially oriented material with a surface coating (first opening control) or not.

Packaging for hospitals

4, 5 or 10 blister packs along with instructions for use in a quantity equal to the number of blister packs are placed in a cardboard pack.

50 or 100 blister packs along with instructions for use in a quantity equal to the number of blister packs are placed in a corrugated cardboard box.

Store in a place protected from light, at a temperature not exceeding 25 °C.
Keep out of the reach of children.
Shelf life: 3 years.
Do not use after the expiration date stated on the package.